Clinical Trial Search

Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants

Primary: Recurrent Infection — 1; 3; 1 participants

Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants

Primary: Number of Participants Eradicated of S. Aureus Carriage - 1 Month After Intervention — 24; 35; 35; 34 Participants

Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…

Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score

Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants

Primary: Medically Attended Skin and Soft Tissue Infections (MA-SSI) — 20.9; 17 percentage of partipants

Primary: Recurrence Rates of Abscesses — 4; 14 participants

Primary: Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization — -781 fg/uL

Primary: Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population — 95; 81; 70; 93 Participants…

Primary: Number of Participants With Recurrent Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization — 2; 3 Participants

Primary: Carrier Rate for Staphylococcus Aureus — 20.8 percentage of subjects

Primary: Time to MRSA Infection — 67; 98; 68; 98 Participants — p=0.026

Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…

Primary: Time to 30-day Mortality — 15; 14 days

Primary: Number of Participants With Antibiotic Usage at the Time of the ED Visit — 97; 96 Participants

Primary: Number of Index Patients Eradicated of S. Aureus Carriage - 1 Month After Performing Decolonization Measures — 39; 35 Participants — p=1.00

Primary: Clinical Improvement at the 48-72 Hour Clinical Follow-up — 94; 97 participants

Primary: Clinical Response at Study Day 4 in the Modified Intent-to-Treat (MITT) Population — 14; 8; 16; 8 participants

Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants

Primary: The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA Colonization — 12; 14; 0 Participants

Primary: Percentage of Participants With Clinical Success — 85; 69 percentage of participants — p=0.009

Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants

Primary: MRSA Transmission — 0.20; 0.02; 0.11; 0.01 Proportion of swabs positive for MRSA

Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035

Primary: Plasma Retapumulin Pharmacokinetic Parameters by Treatment at Days 1 and 3 Evaluated by Plasma AUC After Dosing — 0.8663; 0.3816; 4.2802; 2.0881 ng.h /mL

Primary: Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days — 18; 7 Participants

Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…

Primary: Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit — 132; 136; 57; 62 Participants